BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Au KP, Chok KSH. Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm. World J Gastroenterol 2018; 24(45): 5081-5094 [PMID: 30568386 DOI: 10.3748/wjg.v24.i45.5081] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
Number Citing Articles
1 Li BCW, Chiu J, Shing K, Kwok GGW, Tang V, Leung R, Ma KW, She WH, Tsang J, Chan A, Cheung TT, Lo CM, Yau T. The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants. Adv Ther 2021;38:3900-10. [PMID: 34061324 DOI: 10.1007/s12325-021-01800-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 El-Domiaty N, Saliba F, Vibert E, Karam V, Sobesky R, Ibrahim W, Pittau G, Ciacio O, Salloum C, Amer K, Saeed MA, Shawky JA, Sa Cunha A, Rosmorduc O, Cherqui D, Adam R, Samuel D. Early Versus Late Hepatocellular Carcinoma Recurrence After Transplantation: Predictive Factors, Patterns, and Long-term Outcome. Transplantation 2021;105:1778-90. [PMID: 32890134 DOI: 10.1097/TP.0000000000003434] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Sarici B, Isik B, Yilmaz S. Management of Recurrent HCC After Liver Transplantation. J Gastrointest Cancer 2020;51:1197-9. [PMID: 32839944 DOI: 10.1007/s12029-020-00498-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lee B, Choi Y, Lee W, Park Y, Kim KH, Hyun IG, Han SJ, Cho JY, Yoon YS, Han HS. Timing for Introduction of Total Laparoscopic Living Donor Right Hepatectomy; Initial Experience Based on the Data of Laparoscopic Major Hepatectomy. Transplantation 2021;105:1273-9. [PMID: 32511151 DOI: 10.1097/TP.0000000000003344] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Ho CM, Chen HL, Hu RH, Lee PH. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective. Ther Adv Med Oncol 2019;11:1758835919843463. [PMID: 31065295 DOI: 10.1177/1758835919843463] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Al Jarroudi O, Ulusakarya A, Almohamad W, Afqir S, Morere JF. Anti-Programmed Cell Death Protein 1 (PD-1) Immunotherapy for Metastatic Hepatocellular Carcinoma After Liver Transplantation: A Report of Three Cases. Cureus 2020;12:e11150. [PMID: 33133796 DOI: 10.7759/cureus.11150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Zhou L, Wang J, Lyu SC, Pan LC, Shi XJ, Du GS, He Q. PD-L1+NEUT, Foxp3+Treg, and NLR as New Prognostic Marker with Low Survival Benefits Value in Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:15330338211045820. [PMID: 34605709 DOI: 10.1177/15330338211045820] [Reference Citation Analysis]
8 Zucker KM, Gomez PA, Kezirian O, Mehta S. Pre-Transplant Factors Influencing Rates of Hepatocellular Carcinoma Recurrence in Liver Transplant Recipients. Gastroenterology Res 2021;14:190-3. [PMID: 34267835 DOI: 10.14740/gr1402] [Reference Citation Analysis]
9 Berenguer M, Burra P, Ghobrial M, Hibi T, Metselaar H, Sapisochin G, Bhoori S, Kwan Man N, Mas V, Ohira M, Sangro B, van der Laan LJW. Posttransplant Management of Recipients Undergoing Liver Transplantation for Hepatocellular Carcinoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1143-9. [PMID: 32217940 DOI: 10.1097/TP.0000000000003196] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Ho CM, Lee CH, Lee MC, Zhang JF, Chen CH, Wang JY, Hu RH, Lee PH. Survival After Treatable Hepatocellular Carcinoma Recurrence in Liver Recipients: A Nationwide Cohort Analysis. Front Oncol 2020;10:616094. [PMID: 33598433 DOI: 10.3389/fonc.2020.616094] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li Z, Lin Y, Cheng B, Zhang Q, Cai Y. Identification and Analysis of Potential Key Genes Associated With Hepatocellular Carcinoma Based on Integrated Bioinformatics Methods. Front Genet 2021;12:571231. [PMID: 33767726 DOI: 10.3389/fgene.2021.571231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
13 Tohyama T, Sakamoto K, Tamura K, Nakamura T, Watanabe J, Wakisaka H, Takada Y. Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review. World J Surg Oncol 2020;18:109. [PMID: 32466780 DOI: 10.1186/s12957-020-01873-0] [Reference Citation Analysis]
14 Walburn T, Moon AM, Hayashi PH, Gerber D, Sanoff HK, McGinty KA, Mauro D, Tepper J, Wang K. Stereotactic Body Radiation Therapy for Recurrent, Isolated Hepatocellular Carcinoma Lymph Node Metastasis With or Without Prior Liver Transplantation. Cureus 2020;12:e9988. [PMID: 32983688 DOI: 10.7759/cureus.9988] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Magro B, Pinelli D, De Giorgio M, Lucà MG, Ghirardi A, Carrobio A, Baronio G, Del Prete L, Nounamo F, Gianatti A, Colledan M, Fagiuoli S. Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria. Cancers (Basel) 2021;13:5976. [PMID: 34885087 DOI: 10.3390/cancers13235976] [Reference Citation Analysis]
16 Chee J, Lee GH, Ooi LY, Seet JE, Loh T, Ng LS. Parapharyngeal metastasis in hepatocellular carcinoma-a rare entity. Int J Oral Maxillofac Surg 2021:S0901-5027(21)00179-X. [PMID: 34090755 DOI: 10.1016/j.ijom.2021.05.012] [Reference Citation Analysis]
17 Akce M, El-rayes BF, Bekaii-saab TS. Frontline therapy for advanced hepatocellular carcinoma: an update. Therap Adv Gastroenterol 2022;15:175628482210861. [DOI: 10.1177/17562848221086126] [Reference Citation Analysis]
18 Au KP, Dai WC, Chi-Yan Chan A, Cheung TT, Lo CM, Chok KS. Performance of Dual-tracer PET-CT for Staging Post-Liver Transplant Hepatocellular Carcinoma Recurrence. Transplant Direct 2021;7:e769. [PMID: 34557586 DOI: 10.1097/TXD.0000000000001213] [Reference Citation Analysis]
19 Guo J, Yang Y, Zhang J, Guo M, Xiang L, Yu S, Ping H, Zhuo L. microRNA‐448 inhibits stemness maintenance and self‐renewal of hepatocellular carcinoma stem cells through the MAGEA6‐mediated AMPK signaling pathway. J Cell Physiol 2019;234:23461-74. [DOI: 10.1002/jcp.28915] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
20 Fang X, Liu Y, Xiao W, Zhao N, Zhu C, Yu D, Zhao Y. Prognostic SLC family genes promote cell proliferation, migration, and invasion in hepatocellular carcinoma. Acta Biochim Biophys Sin (Shanghai) 2021;53:1065-75. [PMID: 34128989 DOI: 10.1093/abbs/gmab076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Yen LH, Sabatino JC. Imaging complications of liver transplantation: a multimodality pictorial review. Abdom Radiol (NY) 2021;46:2444-57. [PMID: 31679057 DOI: 10.1007/s00261-019-02270-2] [Reference Citation Analysis]
22 Zhuang L, Mou HB, Yu LF, Zhu HK, Yang Z, Liao Q, Zheng SS. Immune checkpoint inhibitor for hepatocellular carcinoma recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2020;19:91-3. [PMID: 31706859 DOI: 10.1016/j.hbpd.2019.09.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
23 Au KP, Chok KSH. Immunotherapy after liver transplantation: Where are we now? WJGS 2021;13:1266-77. [DOI: 10.4240/wjgs.v13.i10.1266] [Reference Citation Analysis]
24 Au KP, Chok KSH. Mammalian target of rapamycin inhibitors after post-transplant hepatocellular carcinoma recurrence: Is it too late? World J Gastrointest Surg 2020; 12(4): 149-158 [PMID: 32426094 DOI: 10.4240/wjgs.v12.i4.149] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
25 Shaw BI, Lucander A, Ravindra KV. Very Late Recurrence of Hepatocellular Carcinoma After Orthotopic Liver Transplantation: Presentation and Management. Transplant Direct 2019;5:e483. [PMID: 31579811 DOI: 10.1097/TXD.0000000000000921] [Reference Citation Analysis]
26 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
27 Ossami Saidy RR, Postel MP, Pflüger MJ, Schoening W, Öllinger R, Gül-Klein S, Schmelzle M, Tacke F, Pratschke J, Eurich D. Minimization of Immunosuppressive Therapy Is Associated with Improved Survival of Liver Transplant Patients with Recurrent Hepatocellular Carcinoma. Cancers (Basel) 2021;13:1617. [PMID: 33807392 DOI: 10.3390/cancers13071617] [Reference Citation Analysis]
28 Au KP, Chok KSH. Immunotherapy after liver transplantation: Where are we now? World J Gastrointest Surg 2021; 13(10): 1267-1278 [PMID: 34754394 DOI: 10.4240/wjgs.v13.i10.1267] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Nitta H, Younès A, El-Domiaty N, Karam V, Sobesky R, Vibert E, Coilly A, Maria Antonini T, De Martin E, Cherqui D, Baba H, Rosmorduc O, Adam R, Samuel D, Saliba F. High trough levels of everolimus combined to sorafenib improve patients survival after hepatocellular carcinoma recurrence in liver transplant recipients. Transpl Int 2021;34:1293-305. [PMID: 33932239 DOI: 10.1111/tri.13897] [Reference Citation Analysis]
30 Al-Ameri A, Yu X, Zheng S. Predictors of post-recurrence survival in hepatocellular carcinoma patients following liver transplantation: Systematic review and meta-analysis. Transplant Rev (Orlando) 2021;36:100676. [PMID: 34999555 DOI: 10.1016/j.trre.2021.100676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Vitale G, Gitto S, Campani C, Turco L, Baldan A, Marra F, Morelli MC. Biological therapies in patients with liver disease: are they really lifesavers? Expert Opin Biol Ther 2021;:1-18. [PMID: 34860629 DOI: 10.1080/14712598.2022.2013799] [Reference Citation Analysis]
32 Au KP, Chiang CL, Chan ACY, Cheung TT, Lo CM, Chok KSH. Initial experience with stereotactic body radiotherapy for intrahepatic hepatocellular carcinoma recurrence after liver transplantation. World J Clin Cases 2020; 8(13): 2758-2768 [PMID: 32742986 DOI: 10.12998/wjcc.v8.i13.2758] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]